Skip to main content
    A

    AN2 Therapeutics Inc (ANTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $4.00
    +0.04 (+1.14%)

    Market Cap: $160.38M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    56%(10/18)
    Avg Surprise
    -27.45%
    Streak
    1 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.20
    Range$-0.20 - $-0.20
    2 analysts
    EPS Revisions
    2
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.24+16.7%
    60d ago$-0.24+16.7%
    30d ago$-0.24+16.7%
    7d ago$-0.26+21.6%
    Current$-0.20
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.23
    Range$-0.26 - $-0.19
    2 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    2 analysts
    Last 12 of 19 reported quarters and 2 upcoming estimates
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.23$-0.26 - $-0.19--2--
    Sep 26EST
    		-$-0.20$-0.20 - $-0.20--2
    1
    0
    30d
    		-
    Jun 26
    Reported Aug 11
    		$-0.18$-0.24$-0.25 - $-0.23+25.00%Beat2
    1
    0
    30d
    		+14.3%
    Mar 26
    Reported May 11
    		$-0.29$-0.23$-0.23 - $-0.23-26.09%Miss1
    1
    0
    30d
    		+17.1%
    Dec 25
    Reported Mar 17
    		$-0.29$-0.24$-0.24 - $-0.24-20.83%Miss1
    0
    1
    30d
    		-16.0%
    Sep 25
    Reported Nov 12
    		$-0.31$-0.22$-0.23 - $-0.21-40.91%Miss2
    No revisions (30d)
    		+11.4%
    Jun 25
    Reported Aug 12
    		$-0.21$-0.31$-0.31 - $-0.31+32.26%Beat1
    1
    0
    30d
    		+56.3%
    Mar 25
    Reported May 13
    		$-0.35$-0.27$-0.27 - $-0.25-29.63%Miss2
    1
    0
    30d
    		+37.5%
    Dec 24
    Reported Mar 25
    		$-0.25$-0.27$-0.27 - $-0.27+7.41%Beat1
    No revisions (30d)
    		+56.1%
    Sep 24
    Reported Nov 13
    		$-0.35$-0.39$-0.42 - $-0.32+10.26%Beat3
    No revisions (30d)
    		+46.2%
    Jun 24
    Reported Aug 13
    		$-0.48$-0.59$-0.65 - $-0.51+18.64%Beat4
    No revisions (30d)
    		+40.7%
    Mar 24
    Reported May 14
    		$-0.56$-0.62$-0.67 - $-0.56+9.68%Beat4
    No revisions (30d)
    		+29.1%
    Dec 23
    Reported Mar 28
    		$-0.57$-0.75$-0.83 - $-0.69+24.00%Beat4
    No revisions (30d)
    		+6.6%
    Sep 23
    Reported Nov 9
    		$-0.65$-0.63$-0.75 - $-0.56-3.17%Miss3
    2
    0
    30d
    		-10.2%

    Key Metrics

    Valuation
    P/E Ratio-3.74EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-50.10%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio14.32xQuick Ratio14.32x
    Trading Statistics
    Beta-0.94Avg Volume288.94K
    52-Week High$7.1952-Week Low$1.00

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$4.20
    SMA 20$3.91
    SMA 50$4.74
    SMA 200$4.14
    EMA 10$4.12
    EMA 20$4.18
    EMA 50$4.53
    EMA 200$4.09

    MACD

    Line: -0.14Signal: -0.21Hist: 0.07

    ADX

    ADX: 21.0+DI: 21.7-DI: 26.6

    Aroon & PSAR

    Aroon UpN/A
    Aroon Down44.0
    PSAR$3.79

    Bollinger Bands

    Upper Band$4.74
    Lower Band$3.07
    %B Position4277%(Upper)
    Band Width0.56

    RSI (14-Day)

    Neutral
    44.0

    Momentum Oscillators

    Stoch %K48.9
    Stoch %D54.9
    Williams %R-58.4
    ROC (10d)12.7%
    Momentum0.45
    CCI (20d)16.8
    MFI (14d)55.3

    Volatility Measures

    ATR (14d)$0.36(8.9%)
    StdDev (20d)0.42
    Hist Vol102.9%(High)

    Volume Flow

    VWAP$4.00
    OBV76.0M
    AD Line21.7M
    CMF (20d)-0.054

    Volume Metrics

    Avg Vol (20d)274.3K
    Vol Ratio0.9x
    VWMA (20d)$3.97

    Pivot Points

    R3$4.63
    R2$4.45
    R1$4.20
    Pivot Point$4.01
    S1$3.77
    S2$3.58
    S3$3.33

    Advanced Oscillators

    TSI-11.50
    Ultimate Osc43.9
    KST-132.03

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$80,000$0
    Cost of Revenue$0$0N/A$0$0$0N/A$0$0$0$40,000$0
    Gross Profit$0$0N/A$0$0$0N/A$0$0$0$40,000$0
    Operating Expenses$8.90M$10.55M$9.32M$10.04M$7.22M$11.54M$8.60M$14.01M$15.88M$18.30M$18.82M$18.18M
    R&D$6.02M$6.74M$6.88M$7.00M$3.20M$7.69M$5.40M$8.29M$12.15M$14.65M$14.92M$14.43M
    SG&A$2.88M$3.81M$2.44M$3.04M$4.02M$3.85M$3.21M$3.48M$3.73M$3.64M$3.90M$3.75M
    Operating Income$-8,904,000$-10,551,000$-9,316,000$-10,040,000$-7,216,000$-11,537,000$-8,598,000$-14,014,000$-15,880,000$-18,296,000$-18,815,000$-18,180,000
    Interest Income$720,000$523,000$605,000$687,000$754,000$888,000$1.08M$1.27M$1.45M$1.68M$0$0
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-8,185,000$-10,028,000$-8,710,000$-9,353,000$-6,462,000$-10,649,000$-7,522,000$-12,747,000$-14,435,000$-16,617,000$-16,101,000$-16,707,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,185,000$-10,028,000$-8,710,000$-9,353,000$-6,462,000$-10,649,000$-7,522,000$-12,747,000$-14,435,000$-16,617,000$-16,898,000$-16,707,000
    EBITDA$-8,999,000$-10,632,000$-9,432,000$-10,251,000$-7,515,000$-11,980,000$-9,165,000$-14,745,000$-16,770,000$-19,386,000$-20,121,000$-17,360,000
    EBIT$-8,905,000$-10,551,000$-9,315,000$-10,040,000$-7,216,000$-11,537,000$-8,598,000$-14,014,000$-15,880,000$-18,295,000$-18,815,000$-16,707,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about ANTX

    Government Contracts

    Gov Obligations (TTM)
    $0
    Gov Obligations / Revenue
    N/A
    Obligations YoY
    N/A
    Active Awards
    1
    New Awards (TTM)
    0
    Avg Remaining Term
    1.9 mo

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    News

    AN2 Therapeutics COO Eizen reports $11,925 in stock sale By Investing.com

    Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics (NASDAQ:ANTX), sold 2,826 shares of company common stock for $11,925 to cover tax withholding obligations from Restricted Stock Unit vesting. Following...

    Investing.com UK•11/6/26•Somewhat-Bearish

    AN2 Therapeutics COO Eizen reports $11,925 in stock sale

    Joshua M. Eizen, COO and Chief Legal Officer at AN2 Therapeutics, Inc., sold 2,826 shares of company common stock for $11,925 to cover tax withholding obligations from vested Restricted Stock Units. Following this...

    Investing.com•11/6/26•Neutral

    To cover vesting taxes, AN2 Therapeutics (ANTX) COO sells 2,826 shares.

    Joshua M. Eizen, Chief Operating Officer and Chief Legal Officer of AN2 Therapeutics, Inc. (ANTX), sold 2,826 shares of common stock at $4.22 per share on November 5...

    Stock Titan•11/6/26•Somewhat-Bearish

    AN2 Therapeutics to Present at 2026 Jefferies Global Healthcare Conference in London

    AN2 Therapeutics, Inc. (NASDAQ: ANTX) announced that its Co-Founder, Chairman, President, and CEO, Eric Easom, will present at the Jefferies Global Healthcare Conference in London on Monday, November 16, 2026...

    BioSpace•11/5/26•Somewhat-Bullish

    AN2 Therapeutics Advances Pipeline With Development Candidate Nomination for Hypophosphatasia (HPP)

    AN2 Therapeutics has nominated AN2-504661 as a development candidate for hypophosphatasia (HPP), a rare inherited metabolic bone disease. This novel boron-based oral ENPP1 inhibitor has demonstrated potent and specific...

    Stock Titan•11/4/26•Bullish

    ANTX Valuation and Fair Value

    P/E
    -3.7x
    P/B
    2.4x
    See GNG's fair value

    ANTX Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -50.1%

    ANTX Competitors

    CompanyTicker
    EDAP TMS SAEDAP
    Oramed Pharmaceuticals IncORMP
    OPTIMIZERx CorpOPRX
    Quipt Home Medical CorpQIPT
    Niagen Bioscience, Inc.NAGE
    Anbio Biotechnology Class A Ordinary SharesNNNN
    Zentalis Pharmaceuticals LlcZNTL
    Innate PharmaIPHA

    Sector: Healthcare

    ANTX Earnings: Beat Rate and Next Report

    Beat rate
    4 of 8 quarters (50.0%)
    Average surprise
    -5.3%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.20
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    ANTX Earnings Date

    ANTX reports Mar 15, 2027, after the close. The date is estimated.

    ANTX ETF Holders

    GNG tracks 2 ETFs that hold ANTX. The largest weights:

    1. Vanguard Morningstar Total Stock Market ETF (VTI), <0.01% of the fund
    2. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for ANTX

    See insider activity

    Frequently Asked Questions About ANTX

    When does ANTX report earnings?

    AN2 Therapeutics Inc (ANTX) is expected to report earnings on Mar 15, 2027.

    Does ANTX pay dividends?

    AN2 Therapeutics Inc (ANTX) does not currently pay a regular dividend.

    What is ANTX's market cap?

    AN2 Therapeutics Inc (ANTX) has a market capitalization of $160.38M with a current stock price of $4.00.

    Related stocks

    Sector: Healthcare

    All stocks starting with A

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In